Librexia

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.

This trial is currently in follow-up and is not accepting new patients. To be considered for similar trials, please complete the form below.